Last reviewed · How we verify
NCT05647512
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
Phase 1, PHASE2 trial testing LM-305 in Relapsed or Refractory Multiple Myeloma. Withdrawn.
1 December 2024
Quick facts
| Lead sponsor | LaNova Medicines Limited |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Start date | 18 January 2023 |
| Primary completion | 1 December 2024 |
| Estimated completion | 30 December 2025 |
Drugs / interventions tested
- LM-305 — full drug profile →
- Dexamethasone (dexamethasone) — full drug profile →
Conditions studied
- Relapsed or Refractory Multiple Myeloma — all drugs for Relapsed or Refractory Multiple Myeloma →
- Other Plasma Cell Diseases — all drugs for Other Plasma Cell Diseases →
Sponsor
LaNova Medicines Limited — full company profile →
Who can join
18 and older, any sex, with Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase I/II Study of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.
Abramson HN. · · 2023 · cited 16× · PMID 37958658 · DOI 10.3390/ijms242115674 -
Targeting GPRC5D for multiple myeloma therapy.
Zhou D, Wang Y, Chen C, Li Z, et al · · 2024 · cited 12× · PMID 39342286 · DOI 10.1186/s13045-024-01611-z -
[Research progress in targeting GPRC5D for the treatment of multiple myeloma].
An JY, Pan MM, Ouyang HY, Mi JQ. · · 2024 · cited 2× · PMID 39414618 · DOI 10.3760/cma.j.cn121090-20240322-00109
Verify or expand the search:
- PubMed search for NCT05647512
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed or Refractory Multiple Myeloma
Currently open trials in the same condition.
- NCT07369895 — Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07116616 — A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
- NCT07312188 — A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT06604715 — A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT06574568 — A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
Other LaNova Medicines Limited trials
Trials by the same sponsor.
- NCT07362186 — LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gast · Phase 3 · not yet recruiting
- NCT07387081 — Phase II Study of LM-24C5 · Phase 2 · recruiting
- NCT06682780 — A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT07112222 — A Study of LM-350 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06868199 — A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05647512 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LaNova Medicines Limited
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05647512.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing